LBL-043 / Leads Biolabs - LARVOL DELTA

Lbl-043, a Novel LILRB4xCD3 T Cell Engager, for the Treatment of Relapsed/Refractory Multiple Myeloma (ASH 2024) - "DRF of LBL-043 (0.2~10 mg/kg) in cynomolgus monkeys was well tolerated, and the highest non-severely toxic dose (HNSTD) was considered to be 10 mg/kg. These data support LBL-043 as a promising therapeutic bispecific antibody for the treatment of LILRB4 positive MM patients."

IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • LILRB4

LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of relapsed/refractory multiple myeloma (AACR 2025) - "LBL-043, a novel bispecific antibody targeting CD3 and LILRB4, redirecs T cells to effectively kill MM cells by simultaneously binding MM cells and T cells. It is also shown a great anti-tumor efficacy in NCI-H929 CDX mouse model. DRF of LBL-043 (0.2~10 mg/kg) in cynomolgus monkeys was well tolerated, and HNSTD was 10 mg/kg."

IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • LILRB4

LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of LILRB4 positive leukemia (AACR 2024) - "LBL-043, a novel bispecific antibody targeting CD3 and LILRB4 with affinity differentiation, induces T cell killing of AML cells by simultaneously binding LILRB4 expressed on tumor cells and CD3 on T cells, redirecting T cells to efficiently killing of AML cells. It is also shown a great anti-tumor efficacy in CDX mouse models. These data support LBL-043 as a novel therapeutic bispecific antibody for the treatment of LILRB4 positive AML and CMML leukemia patients."

IO biomarker • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • LILRB4